NanoViricides, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NNVC NYSE American 2830 www.nanoviricides.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NanoViricides, Inc.

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher - Jun 29th, 2026 6:30 am
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan - Jun 25th, 2026 7:00 am
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo - Jun 22nd, 2026 7:30 am
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo - Jun 15th, 2026 6:30 am
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies - Jun 8th, 2026 6:30 am
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides - May 26th, 2026 6:30 am
NanoViricides closes $2M direct offering - May 19th, 2026 7:06 am
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering - May 18th, 2026 9:55 pm
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak - May 18th, 2026 6:34 am
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides - May 18th, 2026 6:30 am
NanoViricides to raise $2M in registered direct offering - May 15th, 2026 8:02 am
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering - May 15th, 2026 6:35 am
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II - May 15th, 2026 6:00 am
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs - May 12th, 2026 6:35 am
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak - May 11th, 2026 7:00 am
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides - May 11th, 2026 6:30 am
NanoViricides to Participate at D. Boral Capital Global Conference in NYC - May 7th, 2026 6:35 am
NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment - May 7th, 2026 6:30 am
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - May 6th, 2026 1:37 pm
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - May 6th, 2026 6:35 am